Another adjuvant treatment that was under investigation involved OC combined with lapatinib, which is a well-known EGFR/HER-2 (Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2) inhibitor used for HER-2 amplified breast cancer. Here, EGFR is linked to breast cancer.